May 10, 2024 03:55 PM EDTUpdated May 12, 07:49 AM

New Biosecure draft features 2032 grandfather clause, five-year grace period for added companies

Lia DeGroot

Drugmakers would have until 2032 to cut ties with WuXi AppTec and other Chinese life sciences companies, according to an updated draft of the closely …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

New Biosecure draft features 2032 grandfather clause, five-year grace period for added companies

Lia DeGroot

Sign up to read this article for free.

FDA rejects Daiichi Sankyo's HER3 ADC, a blow to quick approval plans for Merck partnership

Supreme Court narrowly rejects Purdue bankruptcy plan, says it gives Sacklers too much protection

Grail pioneered multi-cancer tests. But the company’s rough public debut shows the industry could be in trouble

What Coherus' $40M sale of its Humira biosimilar says about the crowded market

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

To tackle a deadly brain disease, scientists devise small but charming epigenetic editing tool

New Biose­cure draft fea­tures 2032 grand­fa­ther clause, five-year grace pe­ri­od for added com­pa­nies

Lia DeGroot

Sign up to read this article for free.

more like this

FDA re­jects Dai­ichi Sanky­o's HER3 ADC, a blow to quick ap­proval plans for Mer­ck part­ner­ship

Supreme Court nar­row­ly re­jects Pur­due bank­rupt­cy plan, says it gives Sack­lers too much pro­tec­tion

Grail pi­o­neered mul­ti-can­cer tests. But the com­pa­ny’s rough pub­lic de­but shows the in­dus­try could be in trou­ble

What Co­herus' $40M sale of its Hu­mi­ra biosim­i­lar says about the crowd­ed mar­ket

Bio­gen is pur­su­ing more deal­mak­ing this year, with plans to spend up to $8B

To tack­le a dead­ly brain dis­ease, sci­en­tists de­vise small but charm­ing epi­ge­net­ic edit­ing tool

New Biosecure draft features 2032 grandfather clause, five-year grace period for added companies

FDA rejects Daiichi Sankyo's HER3 ADC, a blow to quick approval plans for Merck partnership

Supreme Court narrowly rejects Purdue bankruptcy plan, says it gives Sacklers too much protection

Grail pioneered multi-cancer tests. But the company’s rough public debut shows the industry could be in trouble

What Coherus' $40M sale of its Humira biosimilar says about the crowded market

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

To tackle a deadly brain disease, scientists devise small but charming epigenetic editing tool